Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and manufacturing organizations/contract manufacturing organizations (CDMOs/CMOs), including several multi-billion large-scale biomanufacturing projects. What companies are expanding, and where do these expansions stand?
Samsung Biologics, a global contract development and manufacturing organization (CDMO), and Kurma Partners, a European venture capital firm in healthcare and biotechnology, recently announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ portfolio companies.
South Korean CDMO Samsung Biologics has entered into a long-term manufacturing partnership with major drugmaker Pfizer.
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development deal, Samsung said in a regulatory filing.
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of the major investments by the larger CMDOs/CMOs are outlined in this article.
Samsung Biologics has agreed to buy out partner Biogen’s share of their Samsung Bioepis joint venture for up to $2.3 billion. The South Korean group said the deal will accelerate growth in biosimilars and novel therapeutics R&D.
